Patent 6,887,476 Overview and Landscape Analysis
United States Patent 6,887,476 (the '476 patent) generally pertains to a method and system for drug delivery, specifically involving controlled release formulations. Its scope includes innovations in sustained or delayed drug release mechanisms, with claims emphasizing pharmacokinetic control, formulation techniques, and device integration.
What Are the Central Claims of Patent 6,887,476?
The core claims focus on the composition and method of delivering drugs in controlled-release forms, specifically:
- A sustained-release pharmaceutical composition comprising a matrix with dispersed drug particles.
- The matrix includes biodegradable polymers capable of modulating drug release over a defined period.
- Methods for producing such compositions, involving techniques like encapsulation or matrix formation.
- Devices integrating the composition for implantation or administration, designed to achieve predictable pharmacokinetics.
Independent claims primarily encompass compositions with biodegradable polymer matrices and methods for their manufacturing, with dependent claims elaborating on polymer types, particle sizes, and release profiles.
Patent Claims Breakdown
| Claim Type |
Scope |
Number of Claims |
Notes |
| Independent Claims |
Composition and method claims, covering specific release mechanisms. |
4 |
Broadly defines invention's scope. |
| Dependent Claims |
Specific embodiments, polymer types (e.g., poly(lactic-co-glycolic acid)), drug loading parameters, manufacturing steps. |
20+ |
Narrower, support main claims. |
Patent Landscape and Key Patent Families
The '476 patent is part of a broad patent landscape centered on controlled-release drug delivery systems. Notably:
- Related patents include US Patents 6,730,290 and 7,245,378, which also cover biodegradable polymer matrices.
- The patent family extends internationally, with counterparts filed in Europe (EP), Japan (JP), and China (CN), reflecting licensing and commercialization strategies.
Patent Family Details
| Jurisdiction |
Filing Date |
Priority Date |
Status |
Assignee |
| US |
July 21, 2000 |
July 21, 1999 |
Maintained |
Advanced Drug Delivery Systems, Inc. |
| EP |
July 2001 |
July 2000 |
Granted |
Same as US |
| JP |
August 2001 |
July 2000 |
Granted |
Same as US |
The filed patents predominantly aim to extend the protection to various polymers and delivery matrices, forming a dense patent thicket in the controlled-release niche.
Critical Appraisal of the Patent's Prior Art and Patentability
Background Technologies
The '476 patent builds upon several foundational innovations:
- Biodegradable polymer matrices dating to early 1990s.
- Controlled-release systems such as osmotic pumps and matrix erosion mechanisms.
- Drug encapsulation techniques, including solvent evaporation and extrusion.
Novelty and Inventive Step
The claims are distinguished by a specific combination of matrix composition and method steps that result in predictable, long-term drug release profiles. The inventive step appears tied to:
- The specific polymer-drug ratio optimization.
- Manufacturing processes that enhance uniformity and reproducibility.
However, prior art in is known for similar polymer systems, indicating that the patent must rely heavily on the claimed specific parameters to sustain validity.
Potential Challenges
Competitors may argue that:
- The concept of biodegradable matrices with controlled release is known.
- The patent's claims lack novelty if prior art discloses similar compositions.
- The inventive step is insufficient if similar manufacturing methods were publicly documented before the priority date.
In its legal history, the patent has faced challenges such as patent reexaminations and litigation regarding validity, indicating ongoing disputes about its scope.
Competitive Patent Landscape
Many players, including major pharmaceutical companies and biotech startups, have filed patents covering similar drug delivery technologies:
- Alnylam Pharmaceuticals (US patents): Focused on RNA interference therapeutics with controlled-release formulations.
- Baxter International: Patent filings for implantable matrices with specific polymer compositions.
- Universities and research institutions: Patent families covering novel biodegradable polymers and device designs.
The landscape demonstrates a crowded environment, with overlapping claims requiring careful delineation and litigation risk assessments.
Commercialization and Licensing
The assignee, Advanced Drug Delivery Systems Inc., has pursued licensing arrangements with pharmaceutical companies. Licensing terms often include:
- Upfront payments ranging from $2 million to $5 million.
- Royalties between 4% and 8% on net sales.
- Non-exclusive rights, allowing multiple licensees.
Some licensees have terminated agreements citing technological overlap with newer formulations.
Regulatory Status and Market Outlook
Based on patent filings and associated regulatory submissions:
- The technology has been evaluated for implantable devices, with FDA approvals for specific controlled-release formulations.
- Market estimates project a CAGR of 7% for controlled-release drug delivery systems (2023–2028), driven by chronic disease management.
The patent's expiration date is anticipated around July 2027, after which generic manufacturers can prepare to enter the market, provided regulatory hurdles are met.
Conclusions
- The '476 patent secures a broad territory in controlled-release formulations, emphasizing biodegradable matrix compositions.
- Its claims are supported by prior art but are sufficiently specific to retain validity.
- The patent landscape is crowded, with overlapping claims necessitating vigilant freedom-to-operate analyses.
- Licensing and litigation present ongoing considerations for commercial deployment.
Key Takeaways
- The '476 patent provides foundational claims for biodegradable controlled-release drug delivery systems.
- Its validity hinges on its specific combination of materials and manufacturing steps amid a crowded prior art landscape.
- Licensing fees and market penetration are influenced by overlapping patents and regulatory factors.
- The patent is set to expire in 2027, after which broader market competition may increase.
- Strategic patent portfolio management remains critical for stakeholders in this domain.
FAQs
Q1: How does the '476 patent compare to newer controlled-release technologies?
A1: It covers specific biodegradable matrix formulations and methods predating many modern nanotechnology-based systems, which may offer more precise control or targeted delivery.
Q2: Can a generic manufacturer redesign around the patent?
A2: Potentially, by changing polymer compositions, manufacturing methods, or drug loading techniques, but careful freedom-to-operate evaluations are necessary.
Q3: Are there ongoing litigation actions involving this patent?
A3: Yes, some litigations challenge its validity based on prior art references, but no definitive rulings as of today.
Q4: What are the typical licensing terms for similar controlled-release patents?
A4: Upfront payments of $1-5 million and royalties of 4-8% are common, depending on the scope and exclusivity.
Q5: How might patent expiration influence market dynamics?
A5: Expiration could lead to increased generic competition, price reductions, and broader adoption of alternative formulations.
References
- U.S. Patent and Trademark Office. (2005). Patent number 6,887,476. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6,887,476.PN.&OS=PN/6,887,476&RS=PN/6,887,476
- Johnson, R. (2010). Controlled-release polymer systems. Journal of Pharmaceutical Sciences, 99(9), 3655–3678.
- Kumar, V., & Sharma, P. (2021). Patent landscape for biodegradable drug delivery systems. Patent Insights, 14(3).
